PMC9376878_01
PET-CT axial view shows metabolic hyperactivity of the maxillary mass on the left lateral wall.
fphar-13-890546-g001.jpg
PMC9376878_01_fphar-13-890546-g001.jpg
F1
Further molecular analysis and positron emission tomography/computed tomography (PET/CT) showed that this melanoma was a stage IIIc, pT4N3M0, BRAF wild-type melanoma with the lymph node metastasis (Figure 1). Though there was no clinical or radiologic evidence of the liver, bone, cerebral, or pulmonary metastasis at the moment (Figures 1, 2), the surgical therapy seemed to fail because of the rapid progress of melanoma in the lymph node (Figure 3).
PET-CT axial view shows metabolic hyperactivity of the lymph node mass on the left side.
fphar-13-890546-g002.jpg
PMC9376878_01_fphar-13-890546-g002.jpg
F2
Though there was no clinical or radiologic evidence of the liver, bone, cerebral, or pulmonary metastasis at the moment (Figures 1, 2), the surgical therapy seemed to fail because of the rapid progress of melanoma in the lymph node (Figure 3).
MRI image of metastatic melanoma. (A) T2-weighted axial image shows soft tissue mass with ill-defined borders involving the left lateral wall and cervical lymph node metastasis. The lesion is causing compression of oropharynx. (B) Post contrast T2-weighted coronal image shows the enlarged cervical lymph node.
fphar-13-890546-g003.jpg
PMC9376878_01_fphar-13-890546-g003.jpg
F3
Though there was no clinical or radiologic evidence of the liver, bone, cerebral, or pulmonary metastasis at the moment (Figures 1, 2), the surgical therapy seemed to fail because of the rapid progress of melanoma in the lymph node (Figure 3).
(A) Electrocardiogram shows the sinus rhythm with high voltage on the V5 lead before the antitumor therapy. (B) Electrocardiogram shows sinus rhythm with high voltage on the V5 lead after the five-course antitumor therapy.
fphar-13-890546-g004.jpg
PMC9376878_01_fphar-13-890546-g004.jpg
F4
ECG (Figure 4) and ultrasonic cardiogram (UCG) (Figure 5) were also performed to evaluate the cardiac function.
(A,B) Echocardiography before the antitumor therapy. (C,D) Echocardiography after the five-course antitumor therapy.
fphar-13-890546-g005.jpg
PMC9376878_01_fphar-13-890546-g005.jpg
F5
ECG (Figure 4) and ultrasonic cardiogram (UCG) (Figure 5) were also performed to evaluate the cardiac function.